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between erbB3 and IRS-1 in MCF-7, T47-D and BT-474 cells with
HRGb1 treatment enhancing this recruitment and promoting
IRS-1 phosphorylation at tyrosine (Y) 612, a specific PI3-K binding
site. In addition, siRNA knockdown of IRS-1 greatly impaired
HRGb1 signalling via PI3-K/AKT in these cells. This novel interac-
tion may have clinical relevance as immunohistochemical analy-
sis of ER-positive BC patient samples revealed IRS-1 Y612
expression positively correlated with total erbB3, p-AKT and
Ki67 expression. Importantly, we found that association of IRS-1
by erbB3 impaired IRS-1 recruitment by IGF-IR in both MCF-7
and T47D cells, whilst blockade of IGF-1R enhanced erbB3/IRS-1
interaction and sensitised both cell lines to HRGb1. Consequently,
knockdown of IRS-1 reduced HRGb1 action and enhanced the
effects of IGF-IR inhibition in these cells. In conclusion, these
and previous findings suggest that IRS-1 can be recruited to IGF-
1R, EGFR and erbB3 in ER-positive BC cells and this may provide
an adaptive resistance mechanism when these receptors are tar-
geted individually. Consequently co-targeting of IGF-IR and erbB
receptors/IRS-1 may prove to be a more effective strategy for
the treatment of ER-positive BC.
doi:10.1016/j.ejcsup.2010.06.037
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Human Epidermal Receptor 2 (HER2)+ have attracted attention
as a poor prognostic class of breast cancer. However, HER2+
tumours appear to encompass biologically and clinically hetero-
geneous tumours.
In order to refine HER2+ breast cancer, we analysed over 48,000
gene transcripts in 132 invasive breast carcinomas using Artificial
Neural Network analysis and identified high expression of two
novel genes (SOX11, PSMD3) significantly associated HER2+ posi-
tivity. Using a large invasive breast carcinoma cohort (n = 1,298),
prepared as tissue microarrays, we assessed these targets using
immunohistochemistry and investigated associations with clini-
copathological variables, patients’ outcome and ability to refine
HER2+ classification.
PSMD3 nuclear expression was observed in 219/942 (23%) of
tumours and was significantly correlated to HER2 positivity
(p = 0.004), tubule formation (p = 0.047) and NPI (p = 0.007). PSMD3
expression conferred a strong trend towards a longer breast can-
cer specific survival in the whole series (p = 0.065). SOX11 nuclei
staining was observed in 96/869 (3.8%) tumours and was signifi-
cantly associated with ER (p = 0.006) and PSMD3 nuclear
(p < 0.001) positivity and ck14 negativity (p = 0.018) but not HER2.
SOX11 expression did not predict patient clinical outcome in
either the whole series or HER2+ tumours only.
This study confirms the biological and clinical heterogeneity
of HER2+ tumours and the difficulties in translating global gene
expression data into routine practice using immunohistochemis-
try. We have identified two novel genes associated with HER2+
tumours and further studies analysing the role of PSMD3 expres-
sion in this important subtype is warranted.
doi:10.1016/j.ejcsup.2010.06.038
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CULATION OF BREAST CANCER PATIENTS
N.A. Healy, H.M. Heneghan, A.J. Lowery, N. Miller, M.J. Kerin.
Department of Surgery, National University of Ireland, Galway, Ireland
Introduction: Recent seminal findings from our institution indi-
cate that systemic miR-195 and Let-7a levels have potential as
non-invasive breast cancer biomarkers. We aimed to validate
these findings in an expanded cohort and to identify further miR-
NAs which augment the sensitivity and specificity of circulating
miRNAs as diagnostic and prognostic markers for breast cancer.
Methods: The expression levels of nine miRNAs were evaluated
in an expanded cohort of 265 breast cancer patients, 80 non-
breast malignancies (colon, renal, prostate and melanoma) and
63 age-matched disease-free controls using RQ-PCR. Eleven addi-
tional miRNAs were evaluated as potential miRNA endogenous
controls. Advanced QBase plus software and SPSS were used for
biostatistical analysis of the data and correlation with clinico-
pathological variables.
Results: This study confirmed significantly deranged expres-
sion levels of systemic miR-195 and Let-7a and two additional
miRNAs in breast cancer patients compared to disease-free con-
trols. Elevated miR-195 was identified to be breast cancer-specific,
with a sensitivity of 88% and a specificity of 91%. A combination
of three circulating miRNAs, including miR-195 and Let-7a,
increased the discriminatory power of this test for breast cancer
to 94%. Of the eleven candidate miRNAs selected for normalisa-
tion, two were identified to be stably expressed in a subset of
the original cohort and thus are ideal endogenous controls for
blood based miRNA studies.
Conclusion: This study highlights the presence and dysregula-
tion of cancer-specific miRNAs in the circulation of breast cancer
patients and illustrates the potential for this systemic miRNA sig-
nature to aid in the diagnosis and prognostication of this disease.
doi:10.1016/j.ejcsup.2010.06.039
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Background: Trastuzumab was licensed for adjuvant therapy in
early breast cancer (EBC) in the UK in 2006. The objectives of this
multicentre audit were to determine the incidence of HER2+
breast cancers, proportion of HER2+ EBC women who received
Trastuzumab and ascertain reasons why some HER2+ patients
did not receive Trastuzumab.
Methods: Data collected for all invasive breast cancers diag-
nosed at seven UK centres over 18-months from 2007 onwards.
All HER2+ cancers diagnosed by a combination of IHC and FISH
identified using each centre’s database. Case records checked
and reasons noted if they had not received Trastuzumab.
Results: Patients (4488) diagnosed with invasive breast cancer.
645 (14%) were HER2+ cancers, 523 being EBCs. 326 (62%) HER2+
EBCs received Trastuzumab.
Reasons for not receiving Trastuzumab n = 197(%)
Tumour 610 mm, node negative 65(33)
Small node negative tumours (11–20 mm) 18(9)
Age 42(21)
Comorbidities 27(13)
Therapy refused 28(14)
Other reasons 17(9)
Conclusions: Incidence of HER2+ breast cancers is 14%, majority
being EBCs (81%). Only 62% of the HER2+ EBC patients received
Trastuzumab. Whilst the commonest reason for not receiving
Trastuzumab is small node negative tumours (which is compatible
with UK guidelines), an equal number of patients potentially
missed optimal therapy for reasons not noted in the guidelines.
Recent studies havedemonstrated that beingHER2+ is a significant
risk factor for relapse in patients previously perceived to be at low
risk and no HER2+ patient should now be considered low risk.1
Reference:
1. Tovey SM et al. Poor survival outcomes in HER2+ breast cancer
patients with low-grade, node-negative tumours. BJC
2009;100(5):680–3.
doi:10.1016/j.ejcsup.2010.06.040
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Objective: Of the 49,452 breast cancers diagnosed in the UK in
2006, 25,049 (51%) were diagnosed symptomatically in patients
aged 50 and over. This study compares the nature and treatment
of symptomatic invasive cancers in patients aged 50–69 and 70
years or over (‘elderly’).
Methods: Data were extracted from national audit databases
and from the merged cancer registry database linked to HES.
Results: 84% of Patients aged 50–69 had surgery recorded
compared with 55% of patients aged 70 or over. Surgery rates
increased to 79% in ‘elderly’ patients known to be ER negative.
‘Elderly’ patients were more likely to have a mastectomy (61%
versus 50%). For surgically treated tumours, prognostic factors
were similar in both groups: node positivity: 54% in 50–69 ver-
sus 50% in ‘elderly’, ER status (73% ER positive in 50–69 versus
77% in ‘elderly’) and grade (52% Grade 1 or 2 in 50–69 versus
59% in ‘elderly’). For cases with adjuvant therapy data avail-
able, radiotherapy after conserving surgery was slightly lower
in the ‘elderly’ (87% versus 94%), chemotherapy for node posi-
tive patients was much lower in the ‘elderly’ (21% versus 75%)
and more ‘elderly’ patients received hormone therapy (90%
versus 83%).
Conclusion: ‘Elderly’ patients were less likely to receive surgery
or chemotherapy. Patient choice, the presence of co-morbidities,
lack of evidence on the relative risks/benefits of adjuvant therapy
or reduced access to surgery for older patients are factors which
might explain the differential treatment of these patients.
doi:10.1016/j.ejcsup.2010.06.041
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Background: Breast cancer relative survival (BCRS) tends to be
poorer in older women, but the reasons for this are not clear.
We examined the influence of patient and tumour characteristics,
and treatment on BCRS to see if these could explain the age spe-
cific effects.
Methodology: Data for 14,048 female breast cancer patients
diagnosed from 1999 to 2007 aged 50 years or over were obtained
from the Eastern Cancer Registration and Information Centre. We
estimated relative 5- and 10-year survival for patients in four age
groups (50–69, 70–74, 75–79, and 80+). We also modelled relative
excess mortality rate (REM) adjusting for potential confounders.
Covariates included in the analysis were age, TNM stage, histo-
logic grade, ER status, mode of detection, volume at hospital of
diagnosis, and treatment (surgery, radiotherapy, chemotherapy
and hormonal therapy.
Results: Median follow-up time was 4.7 years. Relative 5-
year survival was 90%, 81%, 76% and 68% for patients aged
50–69, 70–74, 75–79 and 80+, respectively. Corresponding rela-
tive 10-year survival was 84%, 77%, 66% and 60%. Similar pat-
terns were seen for both ER+ and ER and for low and high
volume hospitals.
Unadjusted REM was 1.95, 2.86 and 4.30 for patients aged 70–
74, 75–79 and 80+, respectively (50–69 reference). These were
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